DICLOFENAC SODIUM - Generic Drug Details

What are the generic sources for diclofenac sodium and what is the scope of patent protection?

Diclofenac sodium is the generic ingredient in nine branded drugs marketed by Actavis Mid Atlantic, Alembic, Amneal, Amneal Pharms, Aurolife Pharma Llc, Cipla, Encube, Glenmark Pharms Ltd, Hikma, Padagis Israel, Perrigo Pharma Intl, Sun Pharma Canada, Fougera Pharms, Haleon Us Holdings, Altaire Pharms Inc, Bausch And Lomb, Falcon Pharms, Rising, Rubicon Research, Sandoz, Sciegen Pharms, Novartis, Javelin Pharms Inc, Apotex, Epic Pharma Llc, Lupin, Lupin Pharms, Novel Labs Inc, Pai Holdings Pharm, Twi Pharms, Watson Labs Inc, Zydus Lifesciences, Horizon, Nuvo Pharms Inc, Actavis Elizabeth, Aurobindo Pharma Usa, Carlsbad, Chartwell Rx, Micro Labs, Pliva, Roxane, Teva, Teva Pharms, Umedica, Unique, Dexcel Ltd, Ingenus Pharms Llc, Vpna, Pfizer, Actavis Labs Fl Inc, Exela Holdings, Yung Shin Pharm, and Zydus Pharms, and is included in seventy-four NDAs. There are twenty patents protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Diclofenac sodium has forty-two patent family members in fifteen countries.

There are twenty-one drug master file entries for diclofenac sodium. One hundred and twenty-four suppliers are listed for this compound. There are three tentative approvals for this compound.

Summary for DICLOFENAC SODIUM

International Patents:	42
US Patents:	20
Tradenames:	9
Applicants:	53
NDAs:	74
Drug Master File Entries:	21
Finished Product Suppliers / Packagers:	124
Raw Ingredient (Bulk) Api Vendors:	115
Clinical Trials:	168
Patent Applications:	7,360
Drug Prices:	Drug price trends for DICLOFENAC SODIUM
Drug Sales Revenues:	Drug sales revenues for DICLOFENAC SODIUM
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for DICLOFENAC SODIUM
What excipients (inactive ingredients) are in DICLOFENAC SODIUM?	DICLOFENAC SODIUM excipients list
DailyMed Link:	DICLOFENAC SODIUM at DailyMed

See drug prices for DICLOFENAC SODIUM

See drug sales revenues for DICLOFENAC SODIUM

Recent Clinical Trials for DICLOFENAC SODIUM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The Affiliated Hospital of Putian University	NA
Oman Medical Speciality Board	NA
British University In Egypt	PHASE2

See all DICLOFENAC SODIUM clinical trials

Generic filers with tentative approvals for DICLOFENAC SODIUM

Applicant	Application No.	Strength	Dosage Form
		1.5% W/W	SOLUTION;TOPICAL
		2%	SOLUTION;TOPICAL
		2%	SOLUTION;TOPICAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for DICLOFENAC SODIUM

Drug Class	Nonsteroidal Anti-inflammatory Drug Anti-coagulant Calculi Dissolution Agent
Mechanism of Action	Cyclooxygenase Inhibitors Acidifying Activity Calcium Chelating Activity
Physiological Effect	Decreased Prostaglandin Production Decreased Coagulation Factor Activity

Anatomical Therapeutic Chemical (ATC) Classes for DICLOFENAC SODIUM

D11AX	Other dermatologicals
D11A	OTHER DERMATOLOGICAL PREPARATIONS
D11	OTHER DERMATOLOGICAL PREPARATIONS
D	Dermatologicals

M01AB	Acetic acid derivatives and related substances
M01A	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
M01	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
M	Musculo-skeletal system

M02AA	Antiinflammatory preparations, non-steroids for topical use
M02A	TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
M02	TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
M	Musculo-skeletal system

S01BC	Antiinflammatory agents, non-steroids
S01B	ANTIINFLAMMATORY AGENTS
S01	OPHTHALMOLOGICALS
S	Sensory organs

Paragraph IV (Patent) Challenges for DICLOFENAC SODIUM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
DYLOJECT	Injection	diclofenac sodium	37.5 mg/mL, 1 mL single-dose vials	022396	1	2015-12-15
PENNSAID	Topical Solution	diclofenac sodium	2.0%	204623	1	2014-06-03
PENNSAID	Topical Solution	diclofenac sodium	1.5%	020947	1	2012-07-11
SOLARAZE	Topical Gel	diclofenac sodium	3%	021005	1	2009-12-16

US Patents and Regulatory Information for DICLOFENAC SODIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Encube	DICLOFENAC SODIUM	diclofenac sodium	SOLUTION;TOPICAL	217646-001	Apr 9, 2025	AB	RX	No	No
Amneal	DICLOFENAC SODIUM	diclofenac sodium	SOLUTION;TOPICAL	208198-001	Aug 18, 2022	AB	RX	No	No
Roxane	DICLOFENAC SODIUM	diclofenac sodium	TABLET, DELAYED RELEASE;ORAL	074391-001	Jun 29, 1995		DISCN	No	No
Horizon	PENNSAID	diclofenac sodium	SOLUTION;TOPICAL	204623-001	Jan 16, 2014		DISCN	Yes	No	9,220,784

Expired US Patents for DICLOFENAC SODIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	VOLTAREN	diclofenac sodium	TABLET, DELAYED RELEASE;ORAL	019201-002	Jul 28, 1988	3,652,762
Javelin Pharms Inc	DYLOJECT	diclofenac sodium	SOLUTION;INTRAVENOUS	022396-001	Dec 23, 2014	6,407,079
Fougera Pharms	SOLARAZE	diclofenac sodium	GEL;TOPICAL	021005-001	Oct 16, 2000	5,985,850
Fougera Pharms	SOLARAZE	diclofenac sodium	GEL;TOPICAL	021005-001	Oct 16, 2000	5,639,738

International Patents for DICLOFENAC SODIUM

Country	Patent Number	Title	Estimated Expiration
Australia	2007311019	Diclofenac gel
Brazil	PI0717769	FORMULAÇÃO DE GEL, MÉTODO PARA O TRATAMENTO DA OSTEOARTRITE EM UM INDIVÍDUO SOFRENDO DE DOR ARTICULAR, E, USO DE DICLOFENAC DE SÓDIO
Canada	2666398	GEL DE DICLOFENAC (DICLOFENAC GEL)
China	101588791	Diclofenac gel

DICLOFENAC SODIUM Market Dynamics and Financial Trajectory: Pricing, Volume, Generics/OTC, and Revenue Outlook

Last updated: July 13, 2026

Diclofenac sodium is a long-established NSAID with a mature market, heavy generic penetration, and persistent demand driven by chronic musculoskeletal indications and topical switch. Financial trajectory across geographies is constrained by price erosion, but stabilized by (1) sustained volume, (2) higher-value topical and combination products, (3) OTC accessibility in many markets, and (4) ongoing brand repositioning in select formularies. The drug is broadly off-patent in most jurisdictions, so near-term revenue growth is dominated by channel mix and formulation/product lifecycle management rather than exclusive IP-driven pricing power.

---

How big is the diclofenac sodium market and where is revenue concentrated?

Snapshot answer: Revenue is concentrated in markets with mature reimbursement systems and broad NSAID formularies. Demand is split between oral generics and topical prescription/OTC products, with topical delivering higher price-per-unit and a larger share of promotional activity.

Global and regional demand structure

Diclofenac sodium is sold as:

• Oral: tablets/capsules (immediate and modified release, depending on country product)
• Topical: gel/solution patches/medicated rubs (varies by country)
• Combination products: some markets include diclofenac with other actives (country-dependent)
• OTC vs Rx: OTC status is jurisdiction-dependent; where OTC is enabled, volume tends to rise and gross margins compress.

Indication mix that drives volume

• Osteoarthritis and rheumatoid arthritis management (chronic use)
• Acute musculoskeletal pain (shorter cycles but recurring seasonal and injury-driven sales)
• Sports and back pain retail demand, especially for topical

---

What market dynamics shape diclofenac sodium pricing and profitability?

Snapshot answer: Diclofenac sodium pricing is governed by generic competition, regulatory risk perception around NSAID cardiovascular and GI safety, and channel mix between oral low-price generics and higher-priced topical/OTC products.

Key dynamics

1. Generic price erosion

   • Once multiple ANDA entrants exist, pricing typically follows a race-to-low structure in oral dosage forms.
   • Margin recovery is limited because diclofenac has many therapeutic substitutes within NSAID class (ibuprofen, naproxen, aceclofenac, meloxicam, etc.).

2. Topical substitution supports revenue per patient

   • Topical diclofenac tends to face less direct price competition per branded equivalent because it is often structured as gel/patch systems with different excipient platforms and marketing.
   • Formulation and pack size differentiation can blunt pure unit price erosion.

3. Safety-driven formulary narrowing in some systems

   • NSAID class risk creates insurer and national health system scrutiny for long-term high-dose use.
   • This can shift utilization from oral toward topical or toward lower-risk alternatives, depending on the country’s guidance.

4. Regulatory classification impacts sales channels

   • OTC availability boosts volume but generally depresses pricing power.
   • Rx-only arrangements preserve pricing but limit growth.

---

When do diclofenac sodium exclusivity windows end, and how does that affect revenue?

Snapshot answer: In developed markets, diclofenac sodium revenue has long been post-exclusivity. Revenue changes now track generic entry timing by dosage form and jurisdiction, not primary molecule patent life.

Practical revenue timeline (IP-driven vs lifecycle-driven)

• Pre-generic era: Brand oral products and early topical launches carried pricing power.
• Post-generic era: Oral revenue becomes the “volume engine” but with compressed pricing.
• Lifecycle management era:
  • Topical and combination products maintain a pricing gradient.
  • Pack optimization, line extensions, and marketing reallocation affect revenue more than molecule exclusivity.

---

What patent estate exists around diclofenac sodium, and does it still support royalties?

Snapshot answer: For most major jurisdictions, diclofenac sodium is widely generic with limited remaining molecule-level exclusivity. Current patent value is typically tied to formulations, methods of use, delivery systems, and manufacturing rather than diclofenac itself.

What usually remains patent-relevant

• Topical delivery systems: specific gel formulations, patch matrix designs, penetration enhancers
• Dosing regimens and use: sometimes narrow method-of-use claims
• Combination products: fixed-dose co-formulations
• Process patents: crystallization, particle size control, or manufacturing steps

Business implication

Royalties and sustained brand-like returns are usually concentrated in specific topical systems or branded patient programs, not in diclofenac sodium in general.

---

What generic entry risks exist for diclofenac sodium across oral vs topical?

Snapshot answer: Generic entry risk is structurally higher for oral diclofenac (fast follow, many ANDA competitors). Topical generics exist widely too, but differentiation and product-specific patents can slow substitution in select markets.

Oral dosage forms

• Lower formulation complexity increases generic throughput.
• Price pressure is strongest in tendered procurement and national formularies.

Topical dosage forms

• Lower systemic exposure expectations make them popular, but:
  • local regulatory requirements for penetration and bioequivalence can slow entrants
  • formulation patents (when asserted) can create short-term litigation or delay outcomes.

---

What does FDA status and Orange Book reality typically mean for diclofenac sodium?

Snapshot answer: Diclofenac sodium is generally represented in FDA-approved product catalogs through a large number of generic and listed products, with Orange Book listings focused on formulation and method claims rather than molecule-wide exclusivity.

Regulatory consequences for financial trajectory

• Limited exclusivity lift: Revenue is not sustained by Hatch-Waxman exclusivity at the molecule level.
• Merchandising and conversion drive performance:
  • OTC switches
  • payer formulary positioning
  • product line management in topical and combination categories.

---

How does diclofenac sodium compare with other NSAIDs in market performance and price pressure?

Snapshot answer: Diclofenac competes in a saturated NSAID market where most actives suffer similar generic erosion. Differentiation comes from topical adoption rates, patient preference, and guideline positioning.

Competitive comparison (high-level)

• Ibuprofen/naproxen: very high generic penetration; scale-driven volume often leads, especially in retail OTC.
• Meloxicam: sometimes higher payer preference; branded-to-generic transitions vary by market.
• Celecoxib: stronger brand legacy in some geographies but also generic pressure.
• Diclofenac topical: retains market relevance where guideline support and safety perception favor topical NSAIDs.

Business implication

Diclofenac’s strongest commercial lever is channel and formulation mix, not premium pricing.

---

Which commercial channels drive diclofenac sodium revenue growth or decline?

Snapshot answer: Revenue shifts are driven by:

• retail OTC demand growth (volume)
• pharmacy and hospital tender cycles (pricing)
• formulary changes that affect oral-to-topical utilization
• tendered procurement substituting among equivalent generics.

Channel patterns

• Retail OTC: tends to increase utilization; margin is squeezed by competition.
• Hospital/clinic: typically converts to formulary-preferred generics and topical protocols.
• Specialty pain management: smaller share; depends on guideline adoption and patient pathways.

---

What are the typical financial outcomes for companies selling diclofenac sodium?

Snapshot answer: Financial trajectory for manufacturers is dominated by manufacturing scale, supply chain efficiency, and portfolio breadth across dosage forms and pack sizes. Companies with strong topical lines can retain higher average realization than those limited to oral generics.

Profit and revenue drivers

• Average selling price (ASP) compression over time in oral
• Gross margin support in topical due to:
  • differentiated formulation
  • higher willingness-to-pay in some OTC/consumer segments
• Volume resilience because chronic pain indications and repeat demand sustain usage
• Inventory and tender cycle discipline: mitigating margin shocks from competitive bids

---

How do litigation and settlements usually affect diclofenac sodium commercialization?

Snapshot answer: Molecule-level patent litigation is largely historical in diclofenac sodium. Where disputes occur now, they tend to focus on specific topical formulation patents or product-specific process claims, affecting short-term entry timing rather than long-term market structure.

Practical impact on financials

• Settlements typically do not create multi-year monopoly for the molecule.
• They can:
  • delay a specific competitor’s topical or combination product
  • influence launch sequencing and tender participation
  • shift market share temporarily.

---

How strong is the revenue resilience of diclofenac sodium in inflation and demand shocks?

Snapshot answer: Diclofenac sodium exhibits moderate demand resilience due to chronic and recurring indications, but revenue value is highly sensitive to ASP compression.

Shock sensitivity matrix

• Demand shocks (flu season, injury seasons): manageable, with topical picking up episodic demand.
• Pricing shocks (new entrants, tender re-bids): high impact, especially in oral.
• Regulatory shocks (product reclassification, safety wording updates): can shift channel mix rapidly.

---

Key business implications for R&D and licensing: where value still exists in diclofenac sodium portfolios?

Snapshot answer: Licensing and R&D value concentrates on differentiated topical systems, combinations, and patient-adherence formats rather than new oral diclofenac actives.

Highest-value development themes (commercially)

• Novel topical delivery systems with stronger dermal penetration and patient tolerability
• Combination products with complementary actives (where regulatory pathways and safety profiles support)
• Pack and regimen optimization (once-daily or simplified dosing where approved)
• Manufacturing robustness to support tender and contract reliability

---

Key Takeaways

• Diclofenac sodium is a mature, heavily genericized NSAID market with revenue performance driven by channel mix and formulation differentiation, not molecule-level exclusivity.
• Oral products face the strongest price erosion; topical and OTC-linked products typically support better revenue realization through higher-value positioning.
• Financial trajectories for manufacturers depend on scale economics, procurement strategy, and product portfolio coverage across oral and topical formats.
• Competitive pressure is structural: new entrants and tender dynamics compress ASP, while regulatory and safety perceptions influence oral-to-topical utilization patterns.

---

FAQs

1) Why does diclofenac sodium topical pricing hold up better than oral generics in many markets?
Topical products often command higher per-unit price and benefit from differentiation by delivery system, patient preference, and OTC/retail merchandising, which reduces pure price comparability versus oral tablets.

2) What drives diclofenac sodium revenue during competitive tender cycles?
Tender outcomes hinge on bid pricing, supply reliability, compliance record, pack economics, and ability to maintain consistent availability, which collectively determine volume and realized margin.

3) Do diclofenac sodium safety concerns materially change prescription patterns?
They can. In some systems, safety-focused guidance shifts utilization toward lower-risk alternatives or toward topical NSAIDs, changing the dosage-form mix even when overall NSAID demand persists.

4) Are new patents likely to create large exclusivity-based returns for diclofenac sodium?
Large molecule-level exclusivity is generally not the driver. Where patent protection still matters, it tends to be formulation- or product-specific, limiting the scope of exclusivity.

5) What launch strategy is most effective for new entrants in diclofenac sodium?
Entry success most often comes from securing competitive distribution, matching tender requirements, and targeting dosage forms where differentiation and conversion from existing products is more feasible than competing head-on on low-priced oral tablet economics.

---

References (APA)

1. FDA. (n.d.). Drugs@FDA: FDA Approved Drug Products. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
2. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/ob/